Orion Biotech Opportunities Corp. (ORIAU) Prices $200M IPO

Orion Biotech Opportunities Corp. announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIAU” Thursday, May 13.

The new SPAC aims to combine with a North American, European or Asian healthcare company with a biotech focus. Orion Biotech is led by CEO James Huang, VP Chrystyna Bedrij Stecyk alongside CFO and Secretary Mark Kayal and General Counsel, Assistant Secretary and VP Robert Simonds.

Total SPAC deal count for 2021 year-to-date is now 316. This offering is expected to close on Monday, May 17.

Cantor Fitzgerald & Co. is serving as the sole book-running manager of the offering. Kirkland & Ellis LLP is serving as Issuer’s Counsel with Ellenoff Grossman & Schole LLP serving as Underwriter’s Counsel. WithumSmith+Brown PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.